0000000000055090

AUTHOR

Thomas Herrmann

0000-0002-1093-0194

showing 3 related works from this author

Editorial: Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications.

2020

Introduction: gd T cells have been characterized by the expression of a gd T cell receptor (TCR).When the gd TCR and the corresponding ab TCR were first discovered it was assumed that the corresponding cell types were likely to be functionally very similar. However, some 30 years later, we have realized that they are not. Unlike ab T cells, gd T cells (i) sense target antigens independent of MHC molecules; (ii) display NK-cell like innate reactivities, including killing of infected cells as well as microbes; (iii) are able to take up large particulates, including bacteria, and (iv) can act as professional antigen presenting cells. The “stress sensing” abilities of gd T cells have led to a g…

lcsh:Immunologic diseases. Allergy0301 basic medicineCell typeT cellImmunologygd T cells gd T cell receptor antigen recognition killing mechanisms infectious diseases tumor immunology.Major histocompatibility complexLigandsinfectious diseasesCommunicable DiseasesImmunotherapy Adoptiveγδ T cellsγδ T cell receptor03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalLymphocytes Tumor-InfiltratingAntigenAnti-Infective AgentsT-Lymphocyte SubsetsNeoplasmsmedicineImmunology and AllergyAnimalsHumanstumor immunologyGamma delta T cellAntigen-presenting cellSettore MED/04 - Patologia GeneralebiologyT-cell receptorReceptors Antigen T-Cell gamma-deltakilling mechanismsAcquired immune systemCell biologyantigen recognition030104 developmental biologymedicine.anatomical_structurePhenotypeEditorialbiology.proteinlcsh:RC581-607030215 immunologySignal TransductionFrontiers in immunology
researchProduct

S3-Leitlinie „Magenkarzinom” -

2011

Germanmedicine.medical_specialtyEsophagogastric cancerbusiness.industryGeneral surgeryGastroenterologyMEDLINElanguageMedicineGuidelinebusinesslanguage.human_languageZeitschrift für Gastroenterologie
researchProduct

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a pha…

2008

Abstract Background This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer. Patients and methods Cetuximab was administered weekly: 400 mg/m2 initial dose, then 250 mg/m2 and FUFOX: oxaliplatin 50 mg/m2, FA 500 mg/m2 and 5-FU as a 24-h infusion at either 1500 or 2000 mg/m2 administered for 4 weeks followed by a 1-week rest (one cycle). Results Dose-limiting toxicity (grade 3 diarrhea) occurred in 3 of 14 assessable patien…

Malemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.drug_classLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyAntimetaboliteDisease-Free SurvivalFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseOxaliplatinSurgeryIrinotecanErbB ReceptorsOxaliplatinOncologyFluorouracilPatient ComplianceFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct